Get the Stockscreener App
10.03
0.20%
-0.02
After Hours:
10.03
Rapport Therapeutics Inc stock is traded at $10.03, with a volume of 159.84K.
It is down -0.20% in the last 24 hours and up +0.00% over the past month.
See More
Previous Close:
$10.05
Open:
$9.9
24h Volume:
159.84K
Relative Volume:
0.90
Market Cap:
$354.02M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-1.86%
1M Performance:
+0.00%
6M Performance:
-51.03%
1Y Performance:
+0.00%
1-Day Range:
$9.37
$10.33
1-Week Range:
$9.15
$11.07
52-Week Range:
$7.13
$29.74
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Name
Rapport Therapeutics Inc
Sector
Industry
Phone
857-321-8020
Address
1325 BOYLSTON STREET, BOSTON
Compare RAPP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
10.03 | 354.02M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-02-24 | Initiated | Jefferies | Buy |
| Jul-02-24 | Initiated | Stifel | Buy |
| Jul-02-24 | Initiated | TD Cowen | Buy |
Rapport Therapeutics Inc Stock (RAPP) Latest News
Rapport Therapeutics: Too Early To Be Interesting (NASDAQ:RAPP) - Seeking Alpha
Swiss National Bank Purchases New Stake in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Analyzing Neurogene (NASDAQ:NGNE) & Rapport Therapeutics (NASDAQ:RAPP) - Defense World
(RAPP) Long Term Investment Analysis - news.stocktradersdaily.com
Why GameStop Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - Benzinga
Vanda Pharmaceuticals (NASDAQ:VNDA) and Rapport Therapeutics (NASDAQ:RAPP) Financial Contrast - Defense World
Rapport Therapeutics to present data at 2025 AAN meeting - TipRanks
Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting - GlobeNewswire
Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting - GlobeNewswire Inc.
Several Insiders Invested In Rapport Therapeutics Flagging Positive News - Simply Wall St
Positive Signs As Multiple Insiders Buy Rapport Therapeutics Stock - Yahoo Canada Finance
Insider Buying: Rapport Therapeutics Chief Financial Officer Bought US$101k Of Shares - Yahoo Finance
Rapport Therapeutics CFO Troy Ignelzi buys $100,988 in stock - Investing.com
Rapport Therapeutics director Wendy Young acquires $61,249 in stock - Investing.com India
Rapport Therapeutics Executives Acquire Shares - TradingView
Rapport Therapeutics CFO Troy Ignelzi buys $100,988 in stock By Investing.com - Investing.com UK
Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times
Rapport Therapeutics Reports Q4 Net Loss Of $19.98 Mln - Nasdaq
Rapport Therapeutics, Inc. SEC 10-K Report - TradingView
Rapport Therapeutics reports Q4 EPS (57c) vs. ($8.01) last year - TipRanks
Rapport Therapeutics Inc Q4 Net Loss $20.0 Million -March 11, 2025 at 07:20 am EDT - Marketscreener.com
Rhumbline Advisers Has $182,000 Stock Position in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
New York State Common Retirement Fund Acquires New Position in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
(RAPP) On The My Stocks Page - Stock Traders Daily
Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development - BioSpace
Rapport Therapeutics appoints new chief medical officer By Investing.com - Investing.com Canada
Rapport Therapeutics, Inc. Announces Appointment of Jeffrey Sevigny as Chief Medical Officer - Marketscreener.com
Rapport Therapeutics appoints new chief medical officer - Investing.com
Rapport Therapeutics Announces Appointment of Dr. Jeffrey - GlobeNewswire
Rapport Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Rapport Therapeutics (RAPP) Expected to Announce Earnings on Thursday - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 8.5%Here's What Happened - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap UpHere's Why - MarketBeat
How To Trade (RAPP) - Stock Traders Daily
Rapport Therapeutics (NASDAQ:RAPP) Shares Down 5.6%What's Next? - MarketBeat
Jennison Associates LLC Acquires Shares of 62,287 Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Short Interest Down 15.3% in January - MarketBeat
JPMorgan Chase & Co. Purchases Shares of 4,033 Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Trading Up 4.6%Here's What Happened - MarketBeat
J&J-backed Rapport Therapeutics files for $100M IPO - MSN
Rapport Therapeutics (RAPP) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
(RAPP) Proactive Strategies - Stock Traders Daily
Rapport Therapeutics (RAPP) Projected to Post Quarterly Earnings on Thursday - Defense World
‘A really rational IPO environment’: What does it takes for a biotech to go public now? - Fierce Biotech
Barclays PLC Increases Stock Holdings in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Rapport Therapeutics Inc Stock (RAPP) Financials Data
There is no financial data for Rapport Therapeutics Inc (RAPP). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.05%
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):